Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2017

Open Access 01-11-2017 | Original Article

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions

Authors: M. Kussmann, A. Baumann, S. Hauer, P. Pichler, M. Zeitlinger, M. Wiesholzer, H. Burgmann, W. Poeppl, G. Reznicek

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2017

Login to get access

Abstract

For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal®, Nutrineal®, Physioneal® 1.36% and Physioneal® 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C). Drug concentrations over time were determined by using high-performance liquid chromatography coupled to a mass spectrometer. In addition, drug activity was assessed by a disk diffusion method, diluent stability by visual inspection and drug adsorption by comparison of the measured and calculated concentrations. Blank peritoneal dialysis fluids and deionized water were used as comparator solutions. Fosfomycin was stable in all peritoneal dialysis fluids and at each storage condition investigated over the whole study period. The remaining drug concentrations ranged between 94% and 104% of the respective initial concentrations. No significant drug adsorption was observed for any peritoneal dialysis fluid at any storage condition. No relevant reduction of antimicrobial activity was observed. Fosfomycin is compatible with Extraneal®, Nutrineal® and Physioneal® for up to two weeks at refrigeration or room temperature and may be used for home-based therapy. No dose adjustment is needed due to adsorption or degradation.
Literature
1.
go back to reference Li PK-T, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE et al (2016) ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 36:481–508CrossRefPubMed Li PK-T, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE et al (2016) ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 36:481–508CrossRefPubMed
2.
go back to reference Van Esch S, Krediet RT, Struijk DG (2014) 32 years’ experience of peritoneal dialysis-related peritonitis in a University hospital. Perit Dial Int 34:162–170CrossRefPubMedPubMedCentral Van Esch S, Krediet RT, Struijk DG (2014) 32 years’ experience of peritoneal dialysis-related peritonitis in a University hospital. Perit Dial Int 34:162–170CrossRefPubMedPubMedCentral
3.
go back to reference Huang S-T, Chuang Y-W, Cheng C-H, Wu M-J, Chen C-H, Yu T-M et al (2011) Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis. Clin Nephrol 75:416–425CrossRefPubMed Huang S-T, Chuang Y-W, Cheng C-H, Wu M-J, Chen C-H, Yu T-M et al (2011) Evolution of microbiological trends and treatment outcomes in peritoneal dialysis-related peritonitis. Clin Nephrol 75:416–425CrossRefPubMed
4.
go back to reference Zelenitsky SA, Howarth J, Lagace-Wiens P, Sathianathan C, Ariano R, Davis C et al (2016) Microbiological trends and antimicrobial resistance in peritoneal dialysis-related peritonitis, 2005 to 2014. Perit Dial Int 37:170–176CrossRefPubMed Zelenitsky SA, Howarth J, Lagace-Wiens P, Sathianathan C, Ariano R, Davis C et al (2016) Microbiological trends and antimicrobial resistance in peritoneal dialysis-related peritonitis, 2005 to 2014. Perit Dial Int 37:170–176CrossRefPubMed
5.
go back to reference Gorman T, Eisele G, Bailie GR (1995) Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 15:283–284PubMed Gorman T, Eisele G, Bailie GR (1995) Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 15:283–284PubMed
6.
go back to reference de Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29:5–15PubMed de Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29:5–15PubMed
7.
go back to reference Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15:732–739CrossRef Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15:732–739CrossRef
8.
go back to reference Demir T, Buyukguclu T (2017) Fosfomycin: in vitro efficacy against multidrug-resistant isolates beyond urinary isolates. J Glob Antimicrob Resist 8:164–168CrossRefPubMed Demir T, Buyukguclu T (2017) Fosfomycin: in vitro efficacy against multidrug-resistant isolates beyond urinary isolates. J Glob Antimicrob Resist 8:164–168CrossRefPubMed
9.
go back to reference Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE (2009) Fosfomycin for the treatment of infections caused by gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 18:921–944CrossRefPubMed Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE (2009) Fosfomycin for the treatment of infections caused by gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 18:921–944CrossRefPubMed
10.
go back to reference Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND et al (2008) Antimicrobial susceptibility of multidrug-resistant gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 27:439–443CrossRefPubMed Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND et al (2008) Antimicrobial susceptibility of multidrug-resistant gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 27:439–443CrossRefPubMed
11.
go back to reference Giamarellou H, Poulakou G (2009) Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 69:1879–1901CrossRefPubMed Giamarellou H, Poulakou G (2009) Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 69:1879–1901CrossRefPubMed
12.
go back to reference Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI (2009) Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 34:111–120CrossRefPubMed Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI (2009) Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 34:111–120CrossRefPubMed
13.
go back to reference Wilke M, Grube R (2013) Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist 7:1–7CrossRefPubMedPubMedCentral Wilke M, Grube R (2013) Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist 7:1–7CrossRefPubMedPubMedCentral
14.
go back to reference Quentin C, Bouchet JJ, Gaillard I, Bebear C (1990) Stability of fosfomycin and quinolones in peritoneal dialysis solution. J Antimicrob Chemother 25:878–880CrossRefPubMed Quentin C, Bouchet JJ, Gaillard I, Bebear C (1990) Stability of fosfomycin and quinolones in peritoneal dialysis solution. J Antimicrob Chemother 25:878–880CrossRefPubMed
15.
go back to reference Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47:3764–3767CrossRefPubMedPubMedCentral Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47:3764–3767CrossRefPubMedPubMedCentral
16.
go back to reference Tobudic S, Poeppl W, Kratzer C, Vychytil A, Burgmann H (2012) Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids. Eur J Clin Microbiol Infect Dis 31:1327–1334CrossRefPubMed Tobudic S, Poeppl W, Kratzer C, Vychytil A, Burgmann H (2012) Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids. Eur J Clin Microbiol Infect Dis 31:1327–1334CrossRefPubMed
17.
go back to reference Kussmann M, Schuster L, Zeitlinger M, Pichler P, Reznicek G, Wiesholzer M et al (2015) The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against enterococcus faecalis. Eur J Clin Microbiol Infect Dis 34:2257–2263CrossRefPubMed Kussmann M, Schuster L, Zeitlinger M, Pichler P, Reznicek G, Wiesholzer M et al (2015) The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against enterococcus faecalis. Eur J Clin Microbiol Infect Dis 34:2257–2263CrossRefPubMed
18.
go back to reference Kussmann M, Schuster L, Wrenger S, Pichler P, Reznicek G, Burgmann H et al (2016) Influence of different peritoneal dialysis fluids on the in vitro activity of Cefepime, ciprofloxacin, Ertapenem, Meropenem and tobramycin against Escherichia coli. Perit Dial Int 36:662–668CrossRefPubMed Kussmann M, Schuster L, Wrenger S, Pichler P, Reznicek G, Burgmann H et al (2016) Influence of different peritoneal dialysis fluids on the in vitro activity of Cefepime, ciprofloxacin, Ertapenem, Meropenem and tobramycin against Escherichia coli. Perit Dial Int 36:662–668CrossRefPubMed
19.
go back to reference Shalit I, Welch DF, San Joaquin VH, Marks MI (1985) In vitro antibacterial activities of antibiotics against Pseudomonas Aeruginosa in peritoneal dialysis fluid. Antimicrob Agents Chemother 27:908–911CrossRefPubMedPubMedCentral Shalit I, Welch DF, San Joaquin VH, Marks MI (1985) In vitro antibacterial activities of antibiotics against Pseudomonas Aeruginosa in peritoneal dialysis fluid. Antimicrob Agents Chemother 27:908–911CrossRefPubMedPubMedCentral
20.
go back to reference Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME (2009) Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 34:506–515CrossRefPubMed Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME (2009) Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 34:506–515CrossRefPubMed
21.
go back to reference Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A (2006) Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents 1:35–41CrossRef Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A (2006) Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents 1:35–41CrossRef
22.
go back to reference Ribes S, Taberner F, Domenech A, Cabellos C, Tubau F, Liñares J et al (2006) Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus Pneumoniae. J Antimicrob Chemother 57:931–936CrossRefPubMed Ribes S, Taberner F, Domenech A, Cabellos C, Tubau F, Liñares J et al (2006) Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus Pneumoniae. J Antimicrob Chemother 57:931–936CrossRefPubMed
23.
go back to reference Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C (2004) Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 53:848–852CrossRefPubMed Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C (2004) Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 53:848–852CrossRefPubMed
24.
go back to reference Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48:209–217CrossRefPubMed Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48:209–217CrossRefPubMed
25.
go back to reference Michel C, Viron B, Delisle F, Lependoven C, Mignon F (1989) Treatment of peritonitis in continuous ambulatory peritoneal dialysis with a combination of fosfomycin and pefloxacin. Pathol Biol 37:269–271PubMed Michel C, Viron B, Delisle F, Lependoven C, Mignon F (1989) Treatment of peritonitis in continuous ambulatory peritoneal dialysis with a combination of fosfomycin and pefloxacin. Pathol Biol 37:269–271PubMed
26.
go back to reference De Rosa F, Enrico P, Buoncristiani U, Frongillo R (1977) The in-vitro activity of fosfomycin and its pharmacokinetics in subjects with integral renal function, with renal failure and undergoing peritoneal and extracorporeal dialytic treatment. G Ital Chemioter 23:75–80PubMed De Rosa F, Enrico P, Buoncristiani U, Frongillo R (1977) The in-vitro activity of fosfomycin and its pharmacokinetics in subjects with integral renal function, with renal failure and undergoing peritoneal and extracorporeal dialytic treatment. G Ital Chemioter 23:75–80PubMed
27.
go back to reference Bouchet JL, Albin H, Quentin C, de Barbeyrac B, Vinçon G, Martin-Dupont P et al (1988) Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. Clin Nephrol 29:35–40PubMed Bouchet JL, Albin H, Quentin C, de Barbeyrac B, Vinçon G, Martin-Dupont P et al (1988) Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. Clin Nephrol 29:35–40PubMed
28.
go back to reference Bouchet JL, Aparicio M, Vinçon G, Demotes-Mainard F, Quentin C, Bourdenx JP et al (1991) Pharmacokinetic considerations for treatment of bacterial peritonitis during continuous ambulatory peritoneal dialysis. Contrib Nephrol 89:96–107CrossRefPubMed Bouchet JL, Aparicio M, Vinçon G, Demotes-Mainard F, Quentin C, Bourdenx JP et al (1991) Pharmacokinetic considerations for treatment of bacterial peritonitis during continuous ambulatory peritoneal dialysis. Contrib Nephrol 89:96–107CrossRefPubMed
29.
go back to reference Tobudic S, Matzneller P, Stoiser B, Wenisch JM, Zeitlinger M, Vychytil A et al (2012) Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents Chemother 56:3992–3995CrossRefPubMedPubMedCentral Tobudic S, Matzneller P, Stoiser B, Wenisch JM, Zeitlinger M, Vychytil A et al (2012) Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents Chemother 56:3992–3995CrossRefPubMedPubMedCentral
Metadata
Title
Compatibility of fosfomycin with different commercial peritoneal dialysis solutions
Authors
M. Kussmann
A. Baumann
S. Hauer
P. Pichler
M. Zeitlinger
M. Wiesholzer
H. Burgmann
W. Poeppl
G. Reznicek
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3051-3

Other articles of this Issue 11/2017

European Journal of Clinical Microbiology & Infectious Diseases 11/2017 Go to the issue